Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D0F4SF
|
|||
Former ID |
DNC001755
|
|||
Drug Name |
ISIS 150453
|
|||
Drug Type |
Antisense drug
|
|||
Indication | Discovery agent [ICD-11: N.A.] | Investigative | [1] | |
Company |
Isis Pharmaceuticals
|
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | SOD1 messenger RNA (SOD1 mRNA) | Target Info | . | [1] |
BioCyc | Reactive oxygen species degradation | |||
KEGG Pathway | Peroxisome | |||
Amyotrophic lateral sclerosis (ALS) | ||||
Huntington's disease | ||||
Prion diseases | ||||
NetPath Pathway | TCR Signaling Pathway | |||
Pathwhiz Pathway | Degradation of Superoxides | |||
Pathway Interaction Database | Validated nuclear estrogen receptor alpha network | |||
FOXA1 transcription factor network | ||||
Reactome | Platelet degranulation | |||
Detoxification of Reactive Oxygen Species | ||||
WikiPathways | Oxidative Stress | |||
Copper homeostasis | ||||
Detoxification of Reactive Oxygen Species | ||||
Nifedipine Activity | ||||
Amyotrophic lateral sclerosis (ALS) | ||||
Dopamine metabolism | ||||
AGE/RAGE pathway | ||||
Folate Metabolism | ||||
Vitamin B12 Metabolism | ||||
Selenium Micronutrient Network |
References | Top | |||
---|---|---|---|---|
REF 1 | US patent application no. 7,132,530, Antisense modulation of superoxide dismutase 1, soluble expression. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.